Avramis VI - Search Results

1

Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Avramis VI, et al. Cancer Chemother Pharmacol. 1989;24(4):203-10. doi: 10.1007/BF00257619. Cancer Chemother Pharmacol. 1989. PMID: 2473850

2

Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.

Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finkelstein J, Reaman G, Hammond GD, Holcenberg JS. Avramis VI, et al. Cancer Res. 1990 Nov 15;50(22):7226-31. Cancer Res. 1990. PMID: 1699658 Clinical Trial.

3

Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.

Antonsson BE, Avramis VI, Nyce J, Holcenberg JS. Antonsson BE, et al. Among authors: avramis vi. Cancer Res. 1987 Jul 15;47(14):3672-8. Cancer Res. 1987. PMID: 2439195

4

Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Avramis VI, Powell WC, Mecum RA. Avramis VI, et al. Cancer Chemother Pharmacol. 1989;24(3):155-60. doi: 10.1007/BF00300235. Cancer Chemother Pharmacol. 1989. PMID: 2472227

5

Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Avramis VI, Powell WC, Mecum RA. Avramis VI, et al. Cancer Chemother Pharmacol. 1989;25(1):19-24. doi: 10.1007/BF00694333. Cancer Chemother Pharmacol. 1989. PMID: 2480187

6

Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.

Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS. Avramis VI, et al. Cancer Res. 1987 Dec 15;47(24 Pt 1):6786-92. Cancer Res. 1987. PMID: 3479250

7

Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.

Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI; Children's Oncology Group. Avramis IA, et al. Among authors: avramis vi. Clin Cancer Res. 2006 Dec 1;12(23):6978-84. doi: 10.1158/1078-0432.CCR-06-1140. Clin Cancer Res. 2006. PMID: 17145817

8

Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Ramilo-Torno LV, Avramis VI. Ramilo-Torno LV, et al. Among authors: avramis vi. Cancer Chemother Pharmacol. 1995;35(3):191-9. doi: 10.1007/BF00686547. Cancer Chemother Pharmacol. 1995. PMID: 7805176

9

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).

Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI. Jarrar M, et al. Among authors: avramis vi. Pediatr Blood Cancer. 2006 Aug;47(2):141-6. doi: 10.1002/pbc.20713. Pediatr Blood Cancer. 2006. PMID: 16425271

10

Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice.

Powell WC, Avramis VI. Powell WC, et al. Among authors: avramis vi. Cancer Chemother Pharmacol. 1988;21(2):117-21. doi: 10.1007/BF00257356. Cancer Chemother Pharmacol. 1988. PMID: 2450689

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters